111 related articles for article (PubMed ID: 38754752)
1. Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools.
Cela I; Capone E; Trevisi G; Sala G
Semin Cancer Biol; 2024 Jun; 101():25-43. PubMed ID: 38754752
[TBL] [Abstract][Full Text] [Related]
2. Circulating biomarkers in patients with glioblastoma.
Müller Bark J; Kulasinghe A; Chua B; Day BW; Punyadeera C
Br J Cancer; 2020 Feb; 122(3):295-305. PubMed ID: 31666668
[TBL] [Abstract][Full Text] [Related]
3. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.
Hallal S; Ebrahimkhani S; Shivalingam B; Graeber MB; Kaufman KL; Buckland ME
Brain Tumor Pathol; 2019 Apr; 36(2):29-39. PubMed ID: 30859343
[TBL] [Abstract][Full Text] [Related]
4. Self-Functionalized Superlattice Nanosensor Enables Glioblastoma Diagnosis Using Liquid Biopsy.
Premachandran S; Haldavnekar R; Ganesh S; Das S; Venkatakrishnan K; Tan B
ACS Nano; 2023 Oct; 17(20):19832-19852. PubMed ID: 37824714
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicles: The key for precision medicine in glioblastoma.
Del Bene M; Osti D; Faletti S; Beznoussenko GV; DiMeco F; Pelicci G
Neuro Oncol; 2022 Feb; 24(2):184-196. PubMed ID: 34581817
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma.
Rackles E; Lopez PH; Falcon-Perez JM
Semin Cancer Biol; 2022 Dec; 87():148-159. PubMed ID: 36375777
[TBL] [Abstract][Full Text] [Related]
7. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy.
Wang J; Liu Y; Liu F; Gan S; Roy S; Hasan I; Zhang B; Guo B
Nanoscale; 2023 Jul; 15(26):10904-10938. PubMed ID: 37337814
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicles in Glioma: From Diagnosis to Therapy.
Basu B; Ghosh MK
Bioessays; 2019 Jul; 41(7):e1800245. PubMed ID: 31188499
[TBL] [Abstract][Full Text] [Related]
9. Canine glioblastoma-derived extracellular vesicles as precise carriers for glioblastoma imaging: Targeting across the blood-brain barrier.
Villa A; De Mitri Z; Vincenti S; Crippa E; Castiglioni L; Gelosa P; Rebecchi M; Tosi D; Brunialti E; Oevermann A; Falleni M; Sironi L; Bello L; Mazzaferro V; Ciana P
Biomed Pharmacother; 2024 Mar; 172():116201. PubMed ID: 38306846
[TBL] [Abstract][Full Text] [Related]
10. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping.
Lane R; Simon T; Vintu M; Solkin B; Koch B; Stewart N; Benstead-Hume G; Pearl FMG; Critchley G; Stebbing J; Giamas G
Commun Biol; 2019; 2():315. PubMed ID: 31453379
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.
Mallawaaratchy DM; Hallal S; Russell B; Ly L; Ebrahimkhani S; Wei H; Christopherson RI; Buckland ME; Kaufman KL
J Neurooncol; 2017 Jan; 131(2):233-244. PubMed ID: 27770278
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
[No Abstract] [Full Text] [Related]
13. Molecular and Circulating Biomarkers of Brain Tumors.
Jelski W; Mroczko B
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34210107
[TBL] [Abstract][Full Text] [Related]
14. The von Willebrand factor stamps plasmatic extracellular vesicles from glioblastoma patients.
Sabbagh Q; André-Grégoire G; Alves-Nicolau C; Dupont A; Bidère N; Jouglar E; Guével L; Frénel JS; Gavard J
Sci Rep; 2021 Nov; 11(1):22792. PubMed ID: 34815502
[TBL] [Abstract][Full Text] [Related]
15. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
[TBL] [Abstract][Full Text] [Related]
16. Extracellular Vesicles from Neurosurgical Aspirates Identifies Chaperonin Containing TCP1 Subunit 6A as a Potential Glioblastoma Biomarker with Prognostic Significance.
Hallal S; Russell BP; Wei H; Lee MYT; Toon CW; Sy J; Shivalingam B; Buckland ME; Kaufman KL
Proteomics; 2019 Jan; 19(1-2):e1800157. PubMed ID: 30451371
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rosas-Alonso R; Colmenarejo-Fernández J; Pernía O; Burdiel M; Rodríguez-Antolín C; Losantos-García I; Rubio T; Moreno-Velasco R; Esteban-Rodríguez I; Martínez-Marín V; Yubero P; Costa-Fraga N; Díaz-Lagares A; López-López R; Díaz-Martin E; García JF; Sánchez CV; Gandía-González ML; Moreno-Bueno G; de Castro J; de Cáceres II
Sci Rep; 2024 May; 14(1):11398. PubMed ID: 38762534
[TBL] [Abstract][Full Text] [Related]
19. Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients.
Hallal S; Ebrahim Khani S; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668808
[TBL] [Abstract][Full Text] [Related]
20. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
